Index of Slide Titles
Slide 1:
PLASMA EXCHANGE IN THE TREATMENT OF TTP/HUS WITH LONG TERM FOLLOW UP AND PROGNOSIS
Slide 2:
TTP MAHA
Slide 3:
TYPICAL LESION
Slide 4:
TTP PENTAD
Slide 5:
CAG
1998 BRITISH JOURNAL OF HEMATOLOGY
n = 135
Slide 6:
PATHOPHYSIOLOGY
Slide 7:
TTP
Multiple forms
Slide 8:
CHRONIC RELAPSING
Slide 9:
CONGENITAL
Slide 10:
Untitled
Slide 11:
Untitled
Slide 12:
CASG TTP TRIAL
Slide 13:
OUTCOME MEASURES
Slide 14:
TTP: DEATHS SIX MONTHS
Slide 15:
This slide intentionally left blank
Slide 16:
RESPONSE TO PLASMA EXCHANGE IN 24 PATIENTS WITH TTP, OLIGURIA & AZOTEMIA
Slide 17:
This slide intentionally left blank
Slide 18:
CONCLUSION
Slide 19:
CRYOSUPERNATANT STUDY DESIGN
Slide 20:
RATIONALE FOR POSSIBLE SUPERIORITY OF CRYOSUPERNATANT
Slide 21:
RATIONALE FOR POSSIBLE SUPERIORITY OF CRYOSUPERNATANT
Slide 22:
VWF
(1 U/ml)
Slide 23:
This slide intentionally left blank
Slide 24:
CSP VS FFP
Slide 25:
CONCENTRATION OF VWF IN PLASMA DURING PE THERAPY
Slide 26:
VWF MULTIMERS
Slide 27:
This slide intentionally left blank
Slide 28:
This slide intentionally left blank
Slide 29:
This slide intentionally left blank
Slide 30:
This slide intentionally left blank
Slide 31:
ROLE OF PLATELET ANTIBODIES IN TTP
Slide 32:
MULTIPLE ANTIBODIES IN TTP WESTERN BLOT
Slide 33:
This slide intentionally left blank
Slide 34:
GPIV (CD36; Mr 88,000)
Slide 35:
GPIV (CD36; Mr 88,000)
Slide 36:
Untitled
Slide 37:
CANADA
TTP/HUS
Slide 38:
SDP
Slide 39:
PLAS+SD features
Slide 40:
This slide intentionally left blank
Slide 41:
This slide intentionally left blank
Slide 42:
Untitled
Slide 43:
This slide intentionally left blank
Slide 44:
This slide intentionally left blank
Slide 45:
This slide intentionally left blank
Slide 46:
This slide intentionally left blank
Slide 47:
This slide intentionally left blank
Slide 48:
SAFETY ISSUES
Slide 49:
This slide intentionally left blank
Slide 50:
THIS STUDY WILL:
Slide 51:
CONCLUSIONS
Copyright 2000 |
Reprint Policy
Last Modified: September 1, 2001
